SIR model of the pandemic trend of COVID-19 in Peru

Authors

  • Ronald Eleazar Huarachi Olivera Laboratorio de Biotecnología Celular y Molecular Avanzada (LAB-BIOTBEC), Universidad Nacional de San Agustìn, Arequipa Perù https://orcid.org/0000-0002-3504-3399
  • Antonio Mateo Lazarte RIvera Laboratorio de Biotecnología Celular y Molecular Avanzada (LAB-BIOTBEC), Universidad Nacional de San Agustìn, Arequipa Perù https://orcid.org/0000-0002-9333-0505

DOI:

https://doi.org/10.31053/1853.0605.v78.n3.31142

Keywords:

Coronavirus, epidemic, basic reproduction number

Abstract

The SARS-CoV-2 virus from Europe has reached Peru on March 5 and since March 16 a state of national emergency has been declared, leading to the confinement of the entire population. The objective of this study is to characterize the epidemic evolution of coronavirus disease (COVID-19) applying the SIR model (Susceptible-Infectious-recovered or deceased) during a period of 200 days. The time series data of COVID-19 from March 06 to May 14, 2020 of the Peruvian Ministry of Health was used, presenting estimated cases by varying the basic reproduction number R0. According to the SIR model, the peak of those infected occurs shortly after May 30 from the beginning of the epidemic (day 86) where the total number of infected cases decreases to R0 = 1.5. The results suggest that Peru's current stringent measures can effectively prevent the spread of COVID-19 and should be maintained even with efficient results.

Downloads

Download data is not yet available.

Author Biographies

  • Ronald Eleazar Huarachi Olivera, Laboratorio de Biotecnología Celular y Molecular Avanzada (LAB-BIOTBEC), Universidad Nacional de San Agustìn, Arequipa Perù

    Magister en Biotecnología y estudiante del Doctorado en Ciencias Biológicas, mención Biología Celular y Molecular de la Facultad de Ciencias de la Salud de la Universidad de Antofagasta de Chile. Asesor externo del Laboratorio de Biotecnología Celular y Molecular Avanzada (LAB-BIOTBEC), Universidad Nacional de San Agustín,Arequipa-Perú,

  • Antonio Mateo Lazarte RIvera, Laboratorio de Biotecnología Celular y Molecular Avanzada (LAB-BIOTBEC), Universidad Nacional de San Agustìn, Arequipa Perù

    Profesor de la Facultad de Ciencias Biológicas de la Universidad Nacional de San Agustín de Arequipa, Responsable de LAB-BIOTBEC, Laboratorio de Biotecnología Celular y Molecular Avanzada (LAB-BIOTBEC), Universidad Nacional de San Agustín, Arequipa-Perú.

References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316.

2. Benvenuto D, Giovanetti M, Salemi M, Prosperi M, De Flora C, Junior Alcantara LC, Angeletti S, Ciccozzi M. The global spread of 2019-nCoV: a molecular evolutionary analysis. Pathog Glob Health. 2020 Mar;114(2):64-67. doi: 10.1080/20477724.2020.1725339.

3. Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Med. 2020 Feb;46(2):357-360. doi: 10.1007/s00134-020-05954-2.

4. Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med Virol. 2020 Apr;92(4):455-459. doi: 10.1002/jmv.25688.

5. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 Apr 16;181(2):281-292.e6. doi: 10.1016/j.cell.2020.02.058.

6. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924.

7. Accinelli RA, Xu CMZ, Yachachin-Chávez JM, Cáceres-Pizarro JA, Tafur-Bances KB, Flores-Tejada RG, Paiva Andrade AdC. COVID-19: La pandemia por el nuevo virus SARS-CoV-2. Rev Peru Med Exp Salud Publica. 2020; 37(2). doi: 10.17843/rpmesp.2020.372.5411.

8. Worldometer. COVID-19 coronavirus/cases 2020. Fecha de consulta: 27 de Julio de 2020. Disponible en: https://www.worldometers.info/coronavirus/

9. Aquino M, Garrison C. Peru records first confirmed case of coronavirus, President Vizcarra says. Rueters. 2020 Mar. Disponible en: https://www.reuters.com/article/ushealth-coronavirus-peru/peru-records-first-confirmed-case-of-coronavirus-presidentvizcarra-says-idUSKBN20T1S9

10. Ministerio de Salud. Alerta epidemiológica ante el incremento de casos de COVID-19 en el Perú. 2020 May 13. Disponible en https://cdn.www.gob.pe/uploads/document/file/568926/Alerta_012-2020.pdf

11. Ministerio de Salud. Perú. Sala Situacional COVID-19 Perú. 2020. Disponible en: https://covid19.minsa.gob.pe/sala_situacional.asp

12. Explorer, A. Coronavirus in Peru- the latest updates. 2020 Apr 6. Disponible en: https://amazonas-explorer.com/is-there-coronavirus-in-peru/

13. Writing, M. Coronavirus in Peru: Government decrees mandatory social isolation for 15 days to combat coronavirus. Andina. 2020 Mar 15. Disponible en: https://andina.pe/ingles/noticia-peru-government-decrees-mandatory-social-isolation-for-15-days-to-combat-coronavirus-788411.aspx

14. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020 Mar 13;27(2):taaa021. doi: 10.1093/jtm/taaa021.

15. Manrique AF, González-Chordá, VM, Gutiérrez Lesmes OA, Tellez Piñerez CF, Herrera-Amaya, GM. Modelo SIR de la pandemia de Covid-19 en Colombia. Rev Salud Publica, 2020; 22, 1-9. doi: 10.15446/rsap.V22.85977.

16. Dimitrov NB, Meyers LA. Mathematical approaches to infectious disease prediction and control. Tutorials in Operations Research. Informrs. 2010; 7, pp. 1–25. doi: 10.1287/educ.1100.0075.

17. Pyne S, Vullikanti AKS, Marathe MV. Big Data Applications in Health Sciences and Epidemiology. Handbook of Statistics. 2015;33:171–202. doi: 10.1016/B978-0-444-63492-4.00008-3.

18. Instituto Nacional de Estadística e Informática. Perú tiene una población de 32 millones 131 mil 400 habitantes al 30 de junio del presente año. 2020. Disponible en: http://m.inei.gob.pe/prensa/noticias/peru-tiene-una-poblacion-de-32-millones-131-mil-400-habitantes-al-30-de-junio-del-presente-ano-11659/

19. Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, Gopalakrishna G, Chew SK, Tan CC, Samore MH, Fisman D, Murray M. Transmission dynamics and control of severe acute respiratory syndrome. Science. 2003 Jun 20;300(5627):1966-70. doi: 10.1126/science.1086616.

20. Guerra FM, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, Crowcroft NS. The basic reproduction number (R0) of measles: a systematic review. Lancet Infect Dis. 2017 Dec;17(12):e420-e428. doi: 10.1016/S1473-3099(17)30307-9.

21. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020 Mar 21;395(10228):931-934. doi: 10.1016/S0140-6736(20)30567-5.

22. Canals M, Cáceres D, Alvarado S, Canals A, Cattan PE. Modeling Chagas disease in Chile: From vector to congenital transmission. Biosystems. 2017 Jun-Jul;156-157:63-71. doi: 10.1016/j.biosystems.2017.04.004.

23. Gozzer E, Canchihuamán F, Espinoza R. COVID-19 y la necesidad de actuar para mejorar las capacidades del Perú frente a las pandemias. Rev Peru Med Exp Salud Publica, 2020; 37(2). doi: 10.17843/rpmesp.2020.372.5410.

24. Munayco CV, Tariq A, Soto-Cabezas GG, Reyes, M. F, Valle A, Rojas-Mezarina L, Cabezas C, Loayza M, Chowell G. Peru COVID-19 working group. Early transmission dynamics and control of COVID-19 in a southern hemisphere setting: Lima-Peru, February 29th-March 30th, 2020. Medrxiv. 2020 May 20. doi: 10.1101/2020.04.30.20077594.

25. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032.

26. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9.

27. Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, Pastore Y Piontti A, Mu K, Rossi L, Sun K, Viboud C, Xiong X, Yu H, Halloran ME, Longini IM Jr, Vespignani A. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. 2020 Apr 24;368(6489):395-400. doi: 10.1126/science.aba9757.

28. Fang Y, Nie Y, Penny M. Transmission dynamics of the COVID-19 outbreak and effectiveness of government interventions: A data-driven analysis. J Med Virol. 2020 Jun;92(6):645-659. doi: 10.1002/jmv.25750.

29. Wang H, Wang Z, Dong Y, Chang R, Xu C, Yu X, Zhang S, Tsamlag L, Shang M, Huang J, Wang Y, Xu G, Shen T, Zhang X, Cai Y. Phase-adjusted estimation of the number of Coronavirus Disease 2019 cases in Wuhan, China. Cell Discov. 2020 Feb 24;6:10. doi: 10.1038/s41421-020-0148-0.

30. Aleta A, Moreno Y. Evaluation of the potential incidence of COVID-19 and effectiveness of containment measures in Spain: a data-driven approach. BMC Med. 2020 May 27;18(1):157. doi: 10.1186/s12916-020-01619-5.

Published

2021-08-23

Issue

Section

Original Papers

How to Cite

1.
Huarachi Olivera RE, Lazarte RIvera AM. SIR model of the pandemic trend of COVID-19 in Peru. Rev Fac Cien Med Univ Nac Cordoba [Internet]. 2021 Aug. 23 [cited 2024 Dec. 22];78(3):236-42. Available from: https://revistas.unc.edu.ar/index.php/med/article/view/31142

Similar Articles

1-10 of 366

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)